Addition of bismuth subnitrate to omeprazole plus amoxycillin improves eradication of Helicobacter pylori

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 6, 1998, Pages 557-561

  Carvalho, A F ^a   Fiorelli, L A ^a   Jorge, V N C ^a   Da Silva, C M F ^a   De Nucci, G ^b   Ferraz, J G P ^c   Pedrazzoli, J ^a  

^a S Francisco Univ Medical School   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH NITRATE; OMEPRAZOLE;

ADULT; AGED; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DYSPEPSIA; FEMALE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ULCER HEALING;

ADULT; AGED; AMOXICILLIN; ANTI-ULCER AGENTS; BISMUTH; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PENICILLINS; RANITIDINE; STOMACH ULCER;

EID: 0031810653     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00344.x     Document Type: Article

References (40)

1. Marshall BJ, Goodwin CT, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; ii: 1437-41.
2. George LL, Borody TJ, Andrew's P, et al. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust 1990; 153: 145-9.
3. Coelho LGV, Passos MCF, Chusson Y, et al. Duodenal ulcer and eradication of Helicobacter pylori in a developing country. An 18-month follow-up study. Scand J Gastroenterol 1992; 27: 362-6.
4. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272: 65-99.
5. Peura DA, Graham DY. Helicobacter pylori: consensus reached. Peptic ulcer is on the way to becoming an historic disease. Am J Gastroenterol 1994; 89: 1137-9.
6. Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-27.
7. Hosking SW, Ling TKW, Yung MY, et al. Randomized controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. Br Med J 1992; 305: 502-4.
8. Graham DY, Lew GM, Evans DG, Evans DJ, Klein PD. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled study. Ann Intern Med 1991; 115: 266-9.
9. Logan RPH, Gummet PA, Schaufelberger HD, Greaves RR, Mendelson GM, Walker MM. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994; 35: 323-6.
10. De Boer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on ellicacy of treatment for Helicobacter pylori infection. Lancet 1995; 345: 817-20.
11. Borody TJ, Andrews P, Fracchia G, Brandl S, Shortis NP, Bae H. Omeprazole enhances ellicacy of triple therapy in eradicating Helicobacter pylori. Gut 1995; 37: 477-81.
12. Pounder RE, Willians MP. The treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11(Suppl. 1): 35-41.
13. Labenz J, Gyenes E, Rhul GH, et al. Amoxycillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective randomized and controlled study. Gut 1993; 34: 1167-70.
14. Labenz J, Ruhl GH, Gyenes E, Borsch G. Amoxycillin plus omeprazole: a simple and effective therapeutic regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 1993; 5: 115-16.
15. Penston JG, McColl KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 223-43.
16. Rosch W. Therapie des peptischen Ulkus und der chronischen Gastritis mit Wizmutsalzen. Z Gastroenterol 1987; 25(Suppl. 4): 34-6.
17. Lambert JR, Borromeo J, Eaves ER, Hansky J, Korman M. Efficacy of different dosage regimens of bismuth in eradicating Campylobacter pylori. Gastroenterology 1988; 94: A248(Abstract).
18. Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990; 34: 1637-41.
19. Graham DY, Klein PD, Opekun AR, et al. In vivo susceptibility of Campilobacter pylori. Am J Gastroenterol 1989; 84: 233-8.
20. Lind T, van Zanten V, Unge S, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1996; 1: 138-44.
21. McColm AA, McLaren A, Klingert G, Francis MR, Connolly PC. Ranitidine bismuth citrate: a novel anti-ulcer agent with different physicochemical characteristics and improved biological activity to a bismuth citrate-ranitidine admixture. Aliment Pharmacol Ther 1996; 10: 241-50.
22. Axon ATR, Ireland A, Lancaster MJ, et al. Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1997; 11: 81-7.
23. Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11(Suppl. 1): 27-33.
24. Goodwin CS, Marshall BJ, Blincow ED, Wilson DH, Blackbourn S, Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol 1988; 41: 207-11.
25. Konturek SJ, Kwiecien N, Obtulowicz W, Hezda Z, Olesky J. Effects of colloidal bismuth subcitrate on aspirin-induced gastric microbleeding. DNA loss, and prostaglandin formation in humans. Scand J Gastroenterol 1988; 23: 861-6.
26. Konturek SJ, Bilski J, Kwiecien N, et al. De-Nol stimulates gastric and duodenal alkaline secretion through prostaglandin dependent mechanism. Gut 1987; 28: 1557-63.
27. Pugh S, Lewin MR. Mechanism of action of Roter (bismuth subnitrate) in patients with duodenal ulcer disease and healthy volunteers. J Clin Gastroenterol Hepatol 1990; 5: 382-6.
28. Beherendt WA, Groeger C, Kuhn D, et al. A study relating to bioavailability and renal elimination of bismuth after oral administration of basic bismuth nitrate. Int J Clin Pharmacol Ther Toxicol 1991; 29: 357-60.
29. 205Bi-labelled pharmaceutical bismuth compounds used in the treatment of peptic ulcer disease. Scand J Gastroenterol 1992; 27: 333-6.
30. Nwokolo CU, Prewett EJ, Sawyerr AM, Hudson M, Pounder RE. Lack of bismuth absorption from bismuth subnitrate (roter) tablets. Eur J Gastroenterol Hepatol 1990; 2: 433-5.
31. 2-receptor blockade on bismuth absorption from three ulcer-healing compounds. Gastroenterology 1991; 101: 889-94.
32. Wilhemsen I, Weberg R, Berstad K, et al. Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease. Hepatogastroenterology 1994; 41: 43-7.
33. Wilhelmsen I, Hundal O, Berstad K, Bernstad A. Behandling av magesar med vismutsubnitrat, oksytetracyklin og metronidazol. Tidsskr Nor Laegeforen nr 25 1992; 112: 3197-9.
34. 2 synthesis preserved following cytoprotection by roler (bismuth subnitrate) in the rat alcohol model of gastric ulceration. Br J Exp Path 1988; 69: 833-8.
35. Pugh S, Lewin MR. Mechanism of action of Roter (bismuth subnitrate) in patients with duodenal ulcer disease and healthy volunteers. J Gastroenterol Hepatol 1990; 5: 382-6.
36. ACG Commitce on FDA-Related Matters. Marshall BJ. The use of bismuth in gastroenterology. Am J Gastroenterol 1991; 86: 16-25.
37. Wallace JL, Granger DN. The cellular and molecular basis of gastric mucosal defence. FASEB J 1996; 10: 731-40.
38. Ferraz JGP, Tigley A, Wallace JL. Paradoxical effects of L-arginine on gastric mucosal integrity. Eur J Pharmacol 1994; 260: 107-11.
39. Konturek SJ, Brzozowski T, Majika J, Pytko-Polonczyk J, Stachura J. Inhibition of nitric oxide synthase delays healing of chronic gastric ulcers. Eur J Pharmacol 1993; 239: 215-17.
40. Elliott SN, McKnight W, Cirino G, Wallace JL. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995; 109: 524-30.